Lilly joins the push for non-opioid painkillers

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/dragana991)
(Image: Getty/dragana991)

Related tags: Eli lilly, Eli lilly and company, Opioid, Opioid epidemic, Pain

Eli Lilly acquires exclusive worldwide rights for non-opioid treatment for chronic pain from Centrexion through a licensing agreement.

Centrexion, a late clinical-stage biopharmaceutical company specializing in non-addictive therapies for pain, licensed its non-opioid treatment for chronic pain, CNTX-0290, to Eli Lilly.

The treatment is a small molecule somatostatin receptor type 4 agonist, which Eli Lilly acquired under a potential $997.5m (€891m) agreement.

Per the license, Lilly will pay Centrexion $47.5m upfront, and the latter will be eligible for up to $575m in development and regulatory milestones, and $375m in potential sales milestones and royalties. Lilly and Centrexion may also work together to co-promote CNTX-0290 in the US – should the development of the drug candidate prove successful.

The drug is currently in Phase I clinical trials as a non-opioid treatment for chronic pain conditions.

A push for non-opioids

As public health officials cite that opioid usage in the US is at an epidemic level, and the National Institute on Drug Abuse​ stated that roughly 21% to 29% of individuals prescribed opioids misuse them, there has been a push for the development of non-opioid options for the treatment of pain.

Purdue Pharma recently entered a partnership with Alivio ​to develop a non-opioid painkiller in January 2019. The OxyContin (oxycodone HCI) producer paid Alivio Therapeutics $14.75m upfront to advance the company’s lead drug candidate, ALV-107.

Aside from the push for non-opioid painkillers, the US Department of Defense (DOD) granted Phoenix PharmaLabs $2.7m to develop a non-addictive opioid. The DOD granted the pharmaceutical company the financing to develop its candidate PPL-103 that stimulates three opioid receptors without creating the euphoric feeling associated with opioids.

Related news

Show more

Related products

show more

A Better Approach, for Better Pain Trials

A Better Approach, for Better Pain Trials

Signant Health | 27-Sep-2021 | Technical / White Paper

Pain studies face unique challenges. For one, pain severity can only be truly assessed by the patients themselves. The controlled substances that are often...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Related suppliers

Follow us


View more